X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IO102-IO103 is an off-the-shelf, cancer vaccine designed to kill both tumor cells and immune-suppressive cells. It is under phase 2 clinial trials in combination with pembrolizumab for the treatment of resectable melanoma or squamous cell carcinoma of the head and neck.
Lead Product(s): IO102,IO103,Pembrolizumab
Therapeutic Area: Oncology Product Name: IO102-IO103
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
IO102-IO103 is an investigational immune-modulating cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and PD-L1.
Lead Product(s): IO102,IO103,Pembrolizumab
Therapeutic Area: Oncology Product Name: IO102-IO103
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
The net proceeds will be used for the development of IO102-IO103, an investigational immune-modulating cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and PD-L1.
Lead Product(s): IO102,IO103,Pembrolizumab
Therapeutic Area: Oncology Product Name: IO102-IO103
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Lundbeckfonden BioCapital
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 07, 2023
Details:
IO102-IO103 is an investigational immune-modulating cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and PD-L1.
Lead Product(s): IO102,IO103,Pembrolizumab
Therapeutic Area: Oncology Product Name: IO102-IO103
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2023
Details:
IO102-IO103 is an investigational immune-modulating cancer vaccine designed to target the immunosuppressive mechanisms mediated by the key immunosuppressive proteins indoleamine 2,3-dioxygenase (IDO) and PD-L1 with melanoma patients.
Lead Product(s): IO102,IO103,Pembrolizumab
Therapeutic Area: Oncology Product Name: IO102-IO103
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
Under the terms of the agreement, IO Biotech will sponsor the Phase 2 trial and Merck will supply pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.
Lead Product(s): IO102-IO103,Pembrolizumab
Therapeutic Area: Oncology Product Name: IO102-IO103
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 03, 2022
Details:
IO102-IO103, combines two novel immunotherapeutics, IO102 and IO103, which are designed to target IDO and PD-L1 expressing cells, respectively. IDO and PD-L1 are often dysregulated and over-expressed in a wide range of solid tumors.
Lead Product(s): IO102,Nivolumab
Therapeutic Area: Oncology Product Name: IO102
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
IO102-IO103 is an investigational cancer immunotherapy designed to target the immunosuppressive mechanisms mediated by the key proteins indoleamine 2,3-dehydrogenase (IDO) and PD-L1.
Lead Product(s): IO102,IO103,Pembrolizumab
Therapeutic Area: Oncology Product Name: IO102
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
IO102-IO103 is an investigational cancer immunotherapy designed to target the immunosuppressive mechanisms mediated by the key immunosuppressive proteins indoleamine 2,3-dehydrogenase (IDO) and PD-L1.
Lead Product(s): IO102,IO103,Pembrolizumab
Therapeutic Area: Oncology Product Name: IO102
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
IO102-IO103, an investigational cancer immunotherapy designed to target immunosuppressive mechanisms mediated by key proteins indoleamine 2,3-dehydrogenase (IDO) and PD-L1.
Lead Product(s): IO102-IO103,Pembrolizumab
Therapeutic Area: Oncology Product Name: IO102-IO103
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
